2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
62
Neoplasms
7
Neoplasms, Plasma Cell
6
Recurrence
5
Hematologic Neoplasms
4
Renal Insufficiency
3
Paraproteinemias
3
Lymphoma
3
Immunoglobulin Light-chain Amyloidosis
3
Hematologic Diseases
3
Smoldering Multiple Myeloma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms by Histologic Type
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Blood Protein Disorders
2
Purpura
1
Prostatic Neoplasms
1
Neoplasm, Residual
1
Nausea
1
Natural Killer/T-cell Lymphoma
1
Monoclonal Gammopathy of Undetermined Significance
1
Macroglossia
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphadenopathy
1
Leukemia, Plasma Cell
1
Immunoproliferative Disorders
1
Interventions
Dexamethasone
10
fludarabine phosphate
9
Melphalan
9
fludarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Lenalidomide
7
Cyclophosphamide
7
Mycophenolic Acid
6
Bortezomib
6
Tacrolimus
5
Calcium Dobesilate
4
filanesib
3
dexamethasone acetate
3
dexamethasone 21-phosphate
3
daratumumab
3
carfilzomib
3
auricularum
3
Stem Cell Transplantation
3
Sirolimus
3
Filgrastim
3
liposomal doxorubicin
2
ixazomib
2
Steroids
2
Injections, Subcutaneous
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Cytarabine
2
Cyclosporine
2
Carmustine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Plasma Cell
×
isatuximab
×
Clear all
NCT06517017
2025-11-28
UltraFrailMM
University of Utah
Phase 2
Recruiting
40 enrolled